EFFICACY

MINJUVI^® PLUS LENALIDOMIDE HAD CONSISTENT RESPONSE RATES ACROSS PATIENT SUBGROUPS^4,8

In a subgroup exploratory analysis, MINJUVI^® plus lenalidomide had similar activity in patients with or without refractory disease, whether refractory to the most recent previous therapy, refractory to rituximab or with a history of primary refractory DLBCL⁴

Response rate at a median 13.2-month follow up⁴

L-MIND evaluated the safety and efficacy of MINJUVI^® plus lenalidomide in adult patients with transplant ineligible NTE R/R DLBCL who were not candidates for high-dose chemotherapy and autologous stem cell transplant (ASCT),and who had received 1–3 prior systemic regimens (including at least one anti-CD20-containingtherapy).^1,4

Primary endpoint:

ORR, defined as the proportion of complete and partial responders, assessed according to the 2007 International Working Group response criteria for malignant lymphoma⁴

Secondary endpoints:¹

DoR, defined as time from initial CR or partial response (PR) to first observation of progressive disease (PD) as assessed by an independent review committee using the International Working Group response criteria⁴
Progression-free survival (PFS), defined as the time from first dosing to lymphoma progression or death as assessed by an independent review committee
OS, defined as the time from first dosing to date of death
Adverse event (AE), incidence and severity¹

Dosing schedule

MINJUVI^® was administered over 28-day cycles (12 mg/kg intravenously), once weekly during Cycles 1–3, with a loading dose on Day 4 of Cycle 1, then every 2 weeks during Cycles 4–12. Lenalidomide (25 mg orally) was administered on Days 1–21 of Cycles 1–12
Following Cycle 12, progression-free patients received MINJUVI^® twice weekly until disease progression or unacceptable toxicity²

Select baseline characteristics from L-MIND (N=81)¹

	ALL PATIENTS (N=81)
Median age (range)	72 years (41–86 years)
Age >70 years	45 (56%)
Stage III/IV	61 (75%)
ILD	45 (56%)
IPI 3–5	41 (51%)
Median prior treatment lines (range)	2 (1–4)
Cell of origin (by immunohistochemistry) GCB Non-GCB Unknown	39 (48%) 22 (27%) 20 (25%)
Cell of origin (gene expression profiling) GCB Activated B-cell Unclassified Not evaluable Missing	8 (10%) 20 (25%) 6 (7%) 5 (6%) 42 (52%)
Patients with transformed lymphoma B-cell lymphoma Marginal zone lymphoma NHL unspecified histology Case reported by central pathology review	4 (5%) 2 (3%) 1 (1%) 1 (1%)

Data from Duell J, et al. 2021.¹ Additional study details, including full inclusion/exclusion criteria, can be found on the L-MIND trial webpage.⁵

AE, adverse event; ASCT, autologous stem cell transplant; CI, confidence interval; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DoR, duration of response; FAS, full analysis set; GCB, germinal-centre B-cell; ILD, increased lactase dehydrogenase; IPI, International Prognostic Index; NE, not evaluable; NHL, non-Hodgkin lymphoma; NR, not reached; NTE, non-transplant eligible; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; R/R, relapsed/refractory; SD, stable disease; SmPC, Summary of Product Characteristics.

MINJUVI^® PLUS LENALIDOMIDE OFFERS THE POTENTIAL TO ACHIEVE FAVOURABLE RESPONSE RATES IN DLBCL PATIENT GROUPS, WITH OR WITHOUT REFRACTORY DISEASE^4,8

MINJUVI^® SAFETY

Learn about the safety profile of MINJUVI^®

MINJUVI^® SmPC

Local product information

UK Prescribing Information

ROI Prescribing Information

References:

Duell J, et al. Haematologica 2021; 106.
MINJUVI (tafasitamab) SPC. May 2022. https://www.medicines.org.uk/emc/product/13003/smpc. Last accessed, January 2025.
MINJUVI (tafasitamab) EU SmPC. https://www.ema.europa.eu/en/documents/product-information/minjuvi-epar-product-information_en.pdf. Last accessed, January 2024.
Salles G, et al. Lancet Oncol 2020; 21(7): 978–88.
ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02399085; Last accessed, January 2024.
Duell J, et al. J Clin Oncol 2021; 39(Suppl 15): 7513.
Duell J, et al. Hematol Oncol 2021; 39 (Suppl S2): 58–61.
Salles G, et al. Lancet Oncol 2020; 21 (supplementary appendix).

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events in the UK should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Incyte by calling 00‑800‑0002‑7423

Adverse events in ROI should be reported.

Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie

Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800456748

CI, confidence interval; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DoR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; R/R, relapsed/refractory; SmPC, Summary of Product Characteristics; 2L, second line.

MINJUVI^® UK prescribing information MINJUVI^® ROI prescribing information MINJUVI^®SmPC Privacy Policy Cookie Policy Terms of Use

Marketing authorisation holder:

United Kingdom:

Incyte Biosciences UK Ltd,

First Floor Q1, The Square,

Randalls Way, Leatherhead,

KT22 7TW, UK

The MINJUVI logo and the Incyte logo are registered trademarks of Incyte.

IE/MJVI/P/25/0005

Date of preparation: September 2025

EXTERNAL LINK DISCLAIMER

CAUTION

An error occured

EFFICACY

MINJUVI® PLUS LENALIDOMIDE HAD CONSISTENT RESPONSE RATES ACROSS PATIENT SUBGROUPS4,8

Response rate at a median 13.2-month follow up4

L-MIND: AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM, PHASE-II STUDY

Primary endpoint:

Secondary endpoints:1

Dosing schedule

Select baseline characteristics from L-MIND (N=81)1

Median estimated OS in second-line and third-line patients after at least 35 months’ follow up

Median estimated PFS in second-line and third-line patients after at least 35 months’ follow up